The Role of MRE11 in the IL-6/STAT3 Pathway of Lung Cancer Cells

被引:0
|
作者
Wu, Ching-Yuan [1 ,2 ,3 ]
Shu, Li-Hsin [1 ]
Liu, Hung-Te [1 ]
Cheng, Yu-Ching [1 ]
Wu, Yu-Huei [4 ]
Wu, Yu-Heng [5 ]
机构
[1] Chiayi Chang Gung Mem Hosp, Dept Chinese Med, Chiayi 613, Taiwan
[2] Chang Gung Univ, Coll Med, Sch Chinese Med, Taoyuan 333, Taiwan
[3] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan 333, Taiwan
[4] Chang Gung Univ, Dept Biomed Sci, Taoyuan 333, Taiwan
[5] Natl Sun Yat Sen Univ, Dept Elect Engn, Kaohsiung 804, Taiwan
关键词
MRE11; lung cancer; STAT3; IL-6; macrophage; ACTIVATING-FACTOR; STAT3; MACROPHAGE; DNA; INTERLEUKIN-6; PURIFICATION; RECRUITMENT; INVASION; GROWTH; IL-6;
D O I
10.3390/cimb44120418
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
MRE11 is a pivotal protein for ATM activation during double-strand DNA break. ATM kinase activations may act as lung cancer biomarkers. The IL-6/STAT3 pathway plays an important role in tumor metastasis, including lung cancer. However, the mechanism between MRE11 and the IL-6/STAT3 pathway is still unclear. In this study, we discovered that MRE11 can interact with STAT3 under IL-6 treatment and regulate STAT3 Tyr705 phosphorylation. After the knockdown of MRE11 in lung cancer cells, we discovered that IL-6 or the conditional medium of THP-1 cells can induce the mRNA expression of STAT3 downstream genes, including CCL2, in the control cells, but not in MRE11-knockdown lung cancer cells. Moreover, CCL2 secretion was lower in MRE11-knockdown lung cancer cells than in control cells after treatment with the conditional medium of RAW264.7 cells. In addition, MRE11 deficiency in lung cancer cells decreases their ability to recruit RAW 264.7 cells. Furthermore, MRE11 is a potential target for lung cancer therapy.
引用
收藏
页码:6132 / 6144
页数:13
相关论文
共 50 条
  • [1] The role of IL-6 and STAT3 in inflammation and cancer
    Hodge, DR
    Hurt, EM
    Farrar, WL
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (16) : 2502 - 2512
  • [2] Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer
    Lin, Yan
    He, Ziqin
    Ye, Jiazhou
    Liu, Ziyu
    She, Xiaomin
    Gao, Xing
    Liang, Rong
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 13023 - 13032
  • [3] Hepatoprotection via the IL-6/Stat3 pathway
    Taub, R
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (07): : 978 - 980
  • [4] Deregulated Il-6/stat3 Signalling In Lung Cancer Development
    Jenkins, B. J.
    Brooks, G.
    Ruwanpura, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [5] Molecular dynamics of STAT3 on IL-6 signaling pathway in living cells
    Watanabe, K
    Saito, K
    Kinjo, M
    Matsuda, T
    Tamura, M
    Kon, S
    Miyazaki, T
    Uede, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (04) : 1264 - 1273
  • [6] Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway
    Wang, Limin
    Cao, Limin
    Wang, Huimin
    Liu, Boning
    Zhang, Qicheng
    Meng, Zhaowei
    Wu, Xiang
    Zhou, Qinghua
    Xu, Ke
    [J]. ONCOTARGET, 2017, 8 (44) : 76116 - 76128
  • [7] Aspirin inhibits proliferation of gastric cancer cells via IL-6/STAT3 signaling pathway
    Tang, Shunyu
    Liu, Yun
    Liu, Changqing
    Zhao, Jiayun
    [J]. TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (08) : 1655 - 1660
  • [8] Luteolin suppresses the growth of colon cancer cells by inhibiting the IL-6/STAT3 signaling pathway
    Jiang, Jingwen
    Zhu, Fengting
    Zhang, Hui
    Sun, Tao
    Fu, Fangfang
    Chen, Xuewu
    Zhang, Yanhong
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (04) : 1722 - 1732
  • [9] Research progress of cancer stem cells and IL-6/STAT3 signaling pathway in esophageal adenocarcinoma
    Chen, Mei
    Ye, Xiaojun
    Wang, Ruihua
    Poon, Karen
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (01) : 363 - 371
  • [10] The role of IL-6/JAK2/STAT3 signaling pathway in cancers
    Huang, Bei
    Lang, Xiaoling
    Li, Xihong
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12